DAWEX
17.3.2022 17:52:08 CET | Business Wire | Press release
With more than 80% of industrial data[1] remaining unused, the Data Act calls for the need of fundamental measures to regulate data circulation in order to make data more accessible for all. Granting consumers and companies the control over who accesses their data, for what purpose, is a pillar principle to future measures in order to unlock the richness of industrial data and build a regulated, fair European data economy. Dawex Data Exchange technology awards platform orchestrators the capability to keep control over the circulation of data through a secure, trusted data sharing and data exchange environment ensuring visibility of which data is being used, for which usage, under which terms.
In today’s economy where data has become a product with its own value, not limited to its usage, and the source of new revenue streams, Dawex technology allows organizations to create and gather new ecosystems around data exchange platforms that meet regulatory frameworks and addresses traceability and security challenges. Dawex is the leading technology company for data exchange , data marketplace and data hub , whose mission is to facilitate and accelerate secure data circulation between all economic stakeholders.
As the European Data Act stresses the critical importance of industrial data circulation in order to foster European data-driven innovation, Dawex technology has already demonstrated its operational and business value in more than 20 sectors such as agriculture, space, retail, agrifood, automotive, infrastructure, tourism, real estate and mobility by helping organizations in those industries address economical, social and environmental challenges.
The future Data Act is designed to harmonize rules on the fair access to and use of data generated in the EU across all economic sectors. The proposed measures encompass:
- Facilitating access to generated IoT data to boost data-driven innovative services development,
- Rebalancing SMEs’ negotiating power to prevent contractual misconducts in data exchange contracts,
- Allowing public sector bodies access to data held by companies in public emergencies situations,
- Defining new rules for data and cloud interoperability to simplify cloud and edge service providers switch,
- Safeguarding unlawful data access and transfer by non-EU governments.
Dawex Data Exchange solution provides all the means and capabilities for data providers, data users and data exchange service providers to implement the future Data Act principles by delivering the high level of flexibility, traceability, and control available to all parties involved in data exchange. Data products can be clearly defined, accessed, and exchanged under flexible and fully configurable licensing terms, free of charge or against compensation.
“The Data Act’s ambition is to ensure a fair and innovative European data economy by making data more available for reuse to stimulate data-driven innovation.” said Laurent Lafaye, co-CEO at Dawex. “Since its inception, Dawex has been committed to delivering cutting-edge data exchange technology to bring the perfect conditions for secure and compliant data sharing. Dawex Data Exchange solutions are already aligned to what the Data Act proposes.”
Available in white label, Dawex Data Exchange, Data Hub and Data Marketplace solutions are today the only solutions on the market to offer such easy, efficient and highly secure data exchange capabilities.
“The development of Data Exchange technology facilitates the circulation of data between all economic stakeholders, supporting the flexible deployment of data ecosystems and their interconnection.” said Fabrice Tocco, Dawex co-CEO. “The European Data Act is another critical milestone that confirms Dawex vision and its technological direction for data exchange, driving a strong data economy.”
About Dawex
Dawex is the leading technology company for data exchange , data marketplace and data hub . Dawex mission is to facilitate and accelerate secure data circulation between economic stakeholders, institutions and private organizations, contributing to the development of the data economy. Awarded Technology Pioneer by the World Economic Forum, Dawex is a member of Gaia-X and a co-founding member of the Data Exchange Association . Created in 2015, Dawex has offices in France and Canada, expanding business operations to Asia, North America and the Middle East.
[1] Source: European Commission
View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005725/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
